{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Curis, Inc.
Is Curis, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is mildly bearish due to bearish daily moving averages and weekly Bollinger Bands, despite some mixed signals from the MACD and RSI.
Who are in the management team of Curis, Inc.?
As of March 2022, the management team of Curis, Inc. includes Martyn Greenacre (Independent Chairman), James Dentzer (President and CEO), and Independent Directors Kenneth Kaitin, Lori Kunkel, and Marc Rubin. They oversee the company's strategic direction and operations.
What does Curis, Inc. do?
Curis, Inc. is a biotechnology company focused on developing cancer treatments, with a market cap of approximately $24.69 million. As of March 2025, it reported net sales of $2 million and a net loss of $11 million.
How big is Curis, Inc.?
As of Jun 18, Curis, Inc. has a market capitalization of 24.69 million and reported net sales of 11.21 million with a net profit of -42.13 million over the latest four quarters. Shareholder's funds are at -6.00 million, with total assets of 42.13 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
